此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

2026年5月7日 更新者:Cellenkos, Inc.
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)

研究概览

详细说明

This clinical trial will be conducted in two parts where the first part of Phase 1b will determine the safety and tolerability of CK0802 in patients with steroid refractory GVHD and the second part of Phase 2a will examine the preliminary efficacy of CK0802 in patients with steroid refractory GVHD

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 1. Age ≥12 years old (first 3 subjects will be ≥ 18 years)
  • 2. Grade 2-4 acute GVHD (aGVHD) at baseline
  • 3. No other prior aGVHD treatment
  • 4. Steroid Refractory
  • Progressed after 3 days of treatment with 2 mg/kg methylprednisolone (MPE)
  • No improvement after 7 days of treatment with 2 mg/kg MPE
  • Progressed to a new organ after treatment with 1 mg/kg MPE for skin or upper gastrointestinal (UGI) aGVHD
  • Progressed from nadir during or after a steroid taper
  • 5. Female subjects of childbearing potential (FPCP) must have a negative urine or serum pregnancy test.
  • 6. Agreed to abide by all protocol required procedures including study-related assessments, visits and long term follow up.
  • 7. Willing and able to provide written informed consent.
  • 8. Signed informed consent

Exclusion Criteria:

  • 1. 30 days prior treatment with any other investigational agent after allogeneic HSCT.
  • 2. Known HIV seropositivity.
  • 3. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility.
  • 4. Subjects with uncontrolled inter-current illness that in the opinion of the investigator would place the subject at greater risk of severe toxicity and/or impair the activity of CK0802.
  • 5. Subjects who are pregnant or breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment Arm
CK0802 Tregs will be administered intravenously at a fixed dose of 100 million Treg cells.

Subjects will receive seven planned doses of CK0802 on study day +1, +3 (+/-1 day), +5 (+/-1 day), +7 (+/- 2 day), +14 (+/- 3 days), +21 (+/-3 days) and +28 (+/-3 days). A total of 7 doses will be administered.

If Day 29 assessment shows PR or MR, then 4 additional weekly infusion of CK0802 Tregs can be administered (study days: 35 (+/- 2 day), 42 (+/- 2 day), 49 (+/- 2 day), and 55(+/- 2 day)), for a total of 11 infusions

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase 1b
大体时间:Day +29

Dose limiting toxicities of CK0802 in SR GVHD as assessed by the incidence and severity of AE and SAEs determined by the NCI-CTCAE Version 6.0.

Non-Hematologic: Any ≥ Grade 3 non-hematologic AE as per CTCAE v6.0 Hematologic: Any new or worsened Grade 4 neutropenia, thrombocytopenia, or anemia compared with baseline that persists for >7 days despite supportive care and is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause.

Death: Death within 28 days that is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause

Day +29
Phase 2a
大体时间:D +29

Overall Response (OR) at day +29. Overall response (OR) will include complete response (CR) and partial response (PR). Response to be determined from the maximum acute GVHD stage and grade in each organ.

Complete Response (CR): Stage 0 in all organs (skin, liver, and GI tract) and no intervening additional therapy Partial Response (PR): Improvement of at least 1 stage in 1 or more organs without progression in other organs, and no intervening additional therapy Overall Response (OR): Includes both CR and PR Very Good PR (VGPR): Improvement by at least one stage in one or more organs and

  • Skin: No rash, or bullae, and residual erythematous rash involving <25% of the body surface
  • Liver: Total serum bilirubin concentration of <2 mg/dL or <25% of baseline at enrollment
  • Gut: Tolerating food or enteral feeding, predominantly formed stools, no overt GI bleeding or abdominal cramping, no more than occasional nausea or vomiting
  • No intervening additional therapy
D +29

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2029年6月30日

研究注册日期

首次提交

2026年5月1日

首先提交符合 QC 标准的

2026年5月1日

首次发布 (实际的)

2026年5月8日

研究记录更新

最后更新发布 (实际的)

2026年5月11日

上次提交的符合 QC 标准的更新

2026年5月7日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

IPD can be shared based on request and after proper de-identifiers to protect individual patient information is in place.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅